Review
Copyright ©The Author(s) 2016.
World J Clin Infect Dis. May 25, 2016; 6(2): 6-21
Published online May 25, 2016. doi: 10.5495/wjcid.v6.i2.6
Table 4 Features of gene expression studies comparing suberoylanilide hydroxamic acid -treated and untreated primary cells
Study characteristicsBeliakova-Bethell et al[96]Reardon et al[100]White et al[99]Mohammadi et al[42]Elliott et al[25]
Cells usedPrimary CD4+ T cellsPrimary CD4+ T cellsPrimary CD4+ T cellsIn vitro primary CD4+ T cell latency modelTotal blood from HIV-infected individuals on cART
Concentration or dose of SAHA0.34 μmol/L0.34, 1, 3, 10 μmol/L1 μmol/L0.5 μmol/L400 mg orally once daily
Time of treatment24 h24 h24 h8 h and 24 h14 d (samples analyzed at 2, 8 h; 1, 14 and 84 d)
Experiment replicates966Not reported9
Gene expression profiling platformMicroarrays (Illumina HT12 Beadchips version 3)Microarrays (Illumina HT12 Beadchips version 3)Microarrays (Illumina HT12 Beadchips version 3)RNA-Seq (polyA RNA library; Illumina HiSeq2000)Microarrays (Illumina Human HT12 version 4)
Methods to identify DEGsMultivariate permutation test (BRB-Array tools)Dose-response analysis using likelihood ratio test (Isogene) with Bonferroni correction (P < 0.05)Linear modeling (limma, FDR P < 0.05)Generalized linear modeling (DESeq, FDR < 0.05)Linear modeling (limma, P < 0.05)
Databases used for functional analysesGO consortium, KEGG and Biocarta pathways (BRB-Array Tools), MetaCore networksGO consortium, KEGG and Biocarta pathways (BRB-Array Tools), MetaCore networksGO consortium, KEGG pathways (FAIME), MetaCore networksReactome pathways Ver.40; MsigDbIPA, MsigDb
Total number of DEGs1847347729821289Not reported